← All trials
NCT03981887
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 17, 2019
- Primary completion
- Jun 22, 2019
- Completion date
- Aug 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- WockhardtLead sponsor
- Spaulding Clinical Research Inc.Overall official - principal investigator
- ClinartisCollaborator
- Keystone Bioanalytical, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.